Remyelination Candidate Opicinumab Failed in Phase 2 Trial in MS, But Biogen Won’t Give Up
May 2017 Although a Phase 2b trial of the remyelination drug candidate opicinumab (also known as anti-LINGO-1 and BIIB033) failed to meet its…
3D Laboratory Cell Growth System Should Speed Up MS Remyelination Research
…
Stuart Schlossman
Trailblazing MS doctor William Sheremata dies just after drug’s FDA approval
…
Stuart Schlossman
Study of Myelin-producing Cells a Step Forward for MS, Other Neurological Disorders.
…
Stuart Schlossman
Instability of Myelin Membranes May Be True Trigger of MS, Study Reports
…
Stuart Schlossman
New Study Unravels How Myelin is Repaired, May Suggest New MS Treatments
…
Stuart Schlossman
Myelin Repair, Shape Changers, Misdiagnoses, and Virtual Reality
…
Stuart Schlossman
Remyelination Studies Abound, But How About a Workable Therapy?
…
Stuart Schlossman
2016 – MS Symposium South Florida – Neurological Aspects of MS and BEYOND…
Neurological Aspects of MS and BEYOND… 2016 MS Symposium in South Florida Features Guest MS Neurologists from Ohio, Alabama and…
Stuart Schlossman
New MS Therapy Seen to Promote Myelin Regeneration in Preclinical Study
RegeneRx Biopharmaceuticals, Inc., announced the publication of a research article detailing the process by which Thymosin beta 4 (Tβ4), the company’s novel…
Stuart Schlossman
